Atty. Dkt. No. 029860-0114



Applicant: Andreas MORELL et al.

Title: POLYPEPTIDES CAPABLE OF FORMING ANTIGEN BINDING

STRUCTURES WITH SPECIFICITY FOR THE RHESUS D ANTIGENS, THE DNA ENCODING THEM AND THE PROCESS FOR THEIR PREPARATION

AND USE

Appl. No.: 09/147,443

Filing Date: 01/21/1999

Examiner: Francois P. Vandervegt

Art Unit: 1644

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents were originally submitted to the USPTO on March 1, 1999. See the attached copy of a PTO date-stamped postcard, indicating submission of 22 references. At the Examiner's request, the listed documents are being resubmitted.

Because the original submission of these documents was timely, submission of this Supplemental IDS should not result in any determination of "delay" by Applicants for purposes of determining Patent Term Adjustment (See 37 CFR §§ 1.701-1.705).

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

## **FEE**

Because the original submission complied with 37 CFR §1.97(b), no fee should be required for this resubmission.

Nonetheless, the Commissioner is hereby authorized to charge any fees that may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

By

FOLEY & LARDNER LLP

Washington Harbour 3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5143

Telephone:

(202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted

Beth A. Burrous Attorney for Applicant Registration No. 35,087

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO		Complete if Known		
INFORMATIO	ON DISCLOSURE	Application Number	09/147,443	
STATEMENT BY APPLICANT MAY 0 6 2004 (use as many sheets as necessary)		Filing Date	01/21/1999	
		First Named Inventor	Andreas Morell	
		Group Art Unit	1644	
		Examiner Name	Francois P. Vandervegt	
Sheet TRADEM	of 2	Attorney Docket Number	029860-0114	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	A1	BARBAS III et al., "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs," <u>Methods: A Comparison to Methods in Enzymology</u> , April 1991, pp. 119-124, Vol. 2, No. 2, Academic Press, Inc.		
	A2	CHÉRIF-ZAHAR et al., "Molecular cloning and protein structure of a human blood group Rh polypeptide," Proc. Natl. Acad. Sci. USA, August 1990, pp. 6243-6247, Vol. 87		
	А3	CRAWFORD et al., "Production of Human Monoclonal Antibody to Rhesus D Antigen," <u>The Lancet,</u> February 19, 1983, pp. 386-388, Vol. I, No. 8321		
	A4	DZIEGIEL et al., "Recombinant Antibody Against the Erythrocyte Antigen, Rhesus D," Abstract No. T513, Journal of Cellular Biochemistry, February 26-April 17, 1994, p. 212, Supplement 18D, Wiley-Liss		
	A5	HUGHES-JONES, "Human Monoclonal Antibodies and Haemolytic Disease of the Newborn," <u>British</u> <u>Journal of Haematology</u> , November 1988, pp. 263-265, Vol. 70, No. 3, Blackwell Scientific Publications		
	A6	ISSITT, "Genetics of the Rh blood group system: some current concepts," <u>Medical Laboratory Sciences</u> , 1988, pp. 395-404, Vol. 45, Blackwell Scientific Publications		
	A7	KOZBOR et al., "The production of monoclonal antibodies from human lymphocytes," <a href="mailto:lmmnology Today">lmmnology Today</a> , 1983, pp. 72-79, 1983, Vol. 4, No. 3, Elsevier Science Publishers B.V.		
	A8	LE VAN KIM et al., "Molecular cloning and primary structure of the human blood group RhD polypeptide," Proc. Natl. Acad. Sci. USA, November 1992, pp. 10925-10929, Vol. 89		
	A9	MOURO et al., "Rearrangements of the Blood Group RhD Gene Associated with the D <sup>VI</sup> Category Phenotype," <u>Blood</u> , February 15, 1994, pp. 1129-1135, Vol. 83, No. 4, The American Society of Hematology	illy	
	A10	PARADIS et al., "Protective Effect of the Membrane Skeleton on the Immunologic Reactivity of the Human Red Cell Rh₀(D) Antigen," <u>The Journal of Immunology</u> , July 1, 1986, pp. 240-244, Vol. 137, No. 1, The American Association of Immunologies		
	A11	PERSSON et al., "Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning," Proc. Natl. Acad. Sci. USA, March 1991, pp. 2432-2436, Vol. 88		
	A12	RACE et al. (Eds.), <u>Blood Groups in Man</u> , 1975, TABLE OF CONTENTS ONLY, Blackwell Scientific Publications		

			$\overline{}$
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

1	Substitute for form 1449B/PTO			Complete if Known		
X	O'' E WEORMATIC	ON DISCLO	SURE	Application Number	09/147,443	
3	STATEMENT BY APPLICANT			Filing Date	01/21/1999	
н				First Named Inventor	Andreas Morell	
٠.				Group Art Unit	1644	
3	(use as many s	heets as ne	cessary)	Examiner Name	Francois P. Vandervegt	
Y	STARREDEMARK 2	of	2	Attorney Docket Number	029860-0114	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>	
	A13	SELINGER, "Immunoprophylaxis for rhesus disease – expensive but worth it?" <u>British Journal of Obstetrics and Gynaecology</u> , June 1991, pp. 509-512, Vol. 98, No. 6, Blackwell Scientific Publications		
	A14	SIEGEL et al., "Isolation of Human Anti-Red Blood Cell Antibodies by Repertoire Cloning," <u>Annals New York Academy of Sciences</u> , September 29, 1995, pp. 547-558, Vol. 764, New York Academy of Sciences, USA		
	A15	TIPPETT et al., "The Rh Antigen D: Partial D Antigens and Associated Low Incidence Antigens," <u>Vox Sanguinis</u> , February 1996, pp. 123-131, Vol. 70, S. Karger AG, Basel		
	A16	VOGEL et al., "Human anti-IgE antibodies by repertoire cloning," <u>Eur. J. Immunol.</u> , May 1994, pp. 1200-1207, Vol. 24, VCH Verlagsgesellschaft mbH, Weinheim		
	A17	WILLIAMSON et al., "Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries," Proc. Natl. Acad. Sci. USA, May 1993, pp. 4141-4145, Vol. 90		
	A18	ZEBEDEE et al., "Human combinatorial antibody libraries to hepatitis B surface antigen," <u>Proc. Natl. Acad. Sci. USA</u> , April 1992, pp. 3175-3179, Vol. 89		
			-	
			-	

***************************************		
Examiner Signature	Date Conside	red

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.



7 Today's Date 3/1/99	mark Office on the date stamped hereon:    Response to Office Action   Consistence   C	
JPH&S Ref 6816/P63221USD Today's Da Serial/Patent No. 09/147, 443 Applicant Andreas MORELL et a Filing Date Docember 34, 1998	The following has been received in the U.S. Patent & Trademark Office on the date stamped hereon:    Combined Declaration, Power of Attorney	